If you have been reading about salt form and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Updated 2026-07-08. Numbers and descriptions here follow the published literature rather than marketing material.
Regulatory treatment varies by country. In the United States, melanotan-2 is not approved for any indication, and products marketed for human use fall outside the approved drug framework. Some other jurisdictions have placed it under prescription controls or listed it as a prohibited or restricted substance. Online listings frequently describe the material as a research chemical, a category that does not carry the same manufacturing and labelling requirements as approved medicines.
Solid peptide material is generally stable when kept cold and dry. Common practice is storage at -20 degrees Celsius or lower, with desiccant and protection from light. Repeated freeze-thaw cycles and exposure to moisture are associated with degradation, aggregation, or loss of material. Once dissolved, stability depends on solvent, concentration, and temperature, and solutions are usually treated as short-lived unless stability data support longer periods. Handling notes typically emphasise minimising time at ambient temperature.
Independent verification is central to quality control because the compound is not produced under pharmaceutical manufacturing standards. Third-party laboratories can measure purity, identity, residual solvents, and microbial contamination, though the scope of testing varies between services. Reported analyses of vendor samples have shown batch-to-batch variation in peptide content and the presence of truncated or oxidized species. How much of this variation reflects synthesis conditions versus storage and shipping is not well characterized. No harmonized reference standard exists for the material as sold.
Handling guidance for melanotan II follows general practice for small synthetic peptides rather than a product-specific monograph. Lyophilized powder is typically kept at minus twenty degrees Celsius or colder, protected from light and moisture, because warmth and humidity accelerate degradation. Once reconstituted, solutions are usually refrigerated and used within a short window, as hydrolysis and microbial growth both become concerns. Repeated freeze-thaw cycles are generally avoided. These conventions come from laboratory peptide chemistry and not from formal stability studies on this specific compound.
Analytical confirmation of identity relies on mass spectrometry, most often coupled to liquid chromatography. Reversed-phase high-performance liquid chromatography separates the peptide from related impurities and provides a purity estimate based on peak area. Electrospray ionization mass spectrometry then confirms the expected molecular mass, while tandem mass spectrometry can map the fragment sequence. For research-grade material, these two techniques together form the standard minimum. Purity figures reported by vendors are frequently not traceable to an independent laboratory.
| Property | Value | Notes |
|---|---|---|
| Solid-state storage | -20 degrees Celsius or lower | Desiccated and protected from light |
| Solution stability | Short and method-dependent | Confirm by stability testing |
| Purity assessment | Reversed-phase HPLC | Reported as area percent |
| Identity confirmation | LC-MS or comparable method | Mass match against expected value |
| Common synonyms | MT-II; melanotan II | Informal and catalogue names |
Regulatory treatment varies by jurisdiction and has changed over time. In several countries the peptide is handled as an unapproved prescription medicine, and import or sale for human use is restricted, while elsewhere it falls under poisons or controlled-substance schedules. Enforcement activity against online vendors has been reported in Australia, New Zealand, the United Kingdom and the United States. Scholarly writing discusses melanotan-2 chiefly as an experimental tool and as a case study in unregulated peptide supply, and its precise legal position in any given country should be checked against current national schedules.
Lyophilised melanotan-2 is comparatively robust when kept dry, cold and dark, and a desiccated powder stored at minus twenty degrees Celsius or below is generally expected to retain its chemical integrity for extended periods. In solution the peptide is far less stable, with degradation proceeding through oxidation of tryptophan and histidine residues, hydrolysis adjacent to the lactam bridge, and aggregation at higher concentrations. Repeated freeze-thaw cycling accelerates loss of the parent peak. Working aliquots are therefore prepared once, held cold, and used without letting the stock return to ambient temperature.
Quality assessment of research-grade peptide rests mainly on reversed-phase high-performance liquid chromatography for purity and on mass spectrometry for identity confirmation. A single main peak above a stated threshold, commonly ninety-eight percent by peak area, is the usual release criterion applied by suppliers. Independent analyses commissioned by laboratories and consumer organisations have repeatedly reported discrepancies between label claims and measured content, including truncated sequences, residual trifluoroacetate, and lower-than-declared peptide mass. Those findings do not establish that every supplier is unreliable, but they indicate that purity figures printed on a vial are claims requiring verification rather than settled facts.
Reversed-phase high-performance liquid chromatography is the routine method for purity assessment. Peptides absorb near 214 nm because of the peptide bond, and a gradient of acetonitrile in water separates the intact peptide from deletion sequences, oxidised products, and earlier-eluting fragments at neutral pH. Electrospray ionisation mass spectrometry provides an orthogonal check: the measured mass must agree with the theoretical value. Amino acid analysis and peptide mapping confirm structure but are used less often. Reference standards remain scarce because the peptide is not described in any pharmacopoeia.
Regulatory treatment varies by country. In the United States the peptide is not approved as a medicine, and products offered for human use may be treated as unapproved new drugs; some states also restrict sale. Australia, the United Kingdom, and European Union member states apply comparable restrictions to unapproved peptide products. Border agencies have seized shipments labelled as research chemicals. Classification may change over time, and the legal position for personal importation is not clearly settled in most published guidance.
Lyophilised melanotan-2 is supplied as a solid, which is more stable than a solution. The material is hygroscopic, so weighing is done quickly, in low humidity, with the container kept sealed. Reconstitution usually uses water for injection or bacteriostatic water, added down the wall of the vial to limit foaming. A reconstituted solution is held at 2 to 8 °C and kept away from light. Repeated freezing and thawing of the same vial is avoided because ice crystal formation and concentration effects degrade the peptide.
Routine characterisation relies on reversed-phase high-performance liquid chromatography with ultraviolet detection near 214 nanometres, using a C18 column and a water-acetonitrile gradient containing trifluoroacetic acid. Electrospray ionisation mass spectrometry confirms the expected molecular mass and can reveal truncated or oxidised by-products that co-elute poorly. Sequence and stereochemistry require additional work, such as peptide mapping or amino acid analysis, because a chromatographic purity figure alone does not distinguish a diastereomer from the target peptide. Independent testing of research-grade material frequently shows measured content below the stated label, so a certificate of analysis is best read together with the method that produced it.
Melanotan-2 is handled in the laboratory as a lyophilised powder that dissolves readily in water, dimethyl sulfoxide and dimethylformamide, with limited solubility in ethanol. Stock solutions prepared in an organic solvent often precipitate when diluted into aqueous buffer, so gradual dilution with mixing is standard practice. The peptide carries a tryptophan residue and a histidine residue, both sensitive to oxidation and to alkaline conditions. Working solutions are therefore kept near neutral to slightly acidic pH, protected from light, and consumed within the same working session whenever that is practical.
In January 1949, President Truman, responding to advice from staff who had worked with IIAA, proposed a globalized version of the program as the fourth element of his overall foreign policy – "Point IV". The purpose of the program was to provide technical knowledge to aid the growth of underdeveloped countries around the world. After a lengthy debate, Congress approved the Point Four Program in 1950 and the Technical Cooperation Administration (TCA) was established within the Department of State in September 1950 to administer it. After an initial attempt to operate in the mode of the old Interdepartmental Committee and to merely coordinate programs of other agencies (such as IIAA), TCA adopted an integrated implementation mechanism in November 1951. In an approach that was greatly expanded after 1953, some early technical assistance projects were implemented by U.S. universities under contract to TCA. University project staff in some cases helped perform administrative functions in TCA missions that were in the process of being set up.
=== Direct === Antibodies that are specific for a particular protein (or group of proteins) are immobilized on a solid-phase substrate such as superparamagnetic microbeads or on microscopic agarose (non-magnetic) beads. The beads with bound antibodies are then added to the protein mixture, and the proteins that are targeted by the antibodies are captured onto the beads via the antibodies; in other words, they become immunoprecipitated.
== Function == The encoded protein, commonly abbreviated IRR, is an orphan receptor and one of three receptor tyrosine kinases in the insulin receptor family, alongside the insulin receptor and insulin-like growth factor 1 receptor. No endogenous peptide or protein ligand is known for IRR. In experimental systems, extracellular pH above approximately 7.9 activates the receptor and triggers autophosphorylation. The Human Protein Atlas classifies INSRR RNA expression as cell type enhanced in renal collecting-duct intercalated cells. In rodents, IRR has been localized to non-A intercalated cells; a rat study reported basolateral localization in type B intercalated cells of the cortical collecting duct. In mice, inactivation of Insrr impairs urinary bicarbonate excretion following alkali loading, supporting a role for the receptor in renal acid–base homeostasis. A 2023 cryo-electron microscopy study of the human IRR ectodomain, combined with mutagenesis and cell-based assays, supported a model in which alkaline pH produces electrostatic repulsion involving pH-sensitive motifs at an interprotomer interface, disrupting the autoinhibited state and promoting a scissor-like rotation into a T-shaped active conformation.
Bacterial culture of H. influenzae is performed on agar plates. The strongest growth is seen on chocolate agar at 37 °C in a CO2-enriched incubator. The ideal CO2 concentration for the culture is ~5%. However adequate growth is often seen on brain-heart infusion agar supplemented with hemin and nicotinamide adenine dinucleotide (NAD) Colonies of H. influenzae appear as convex, smooth, pale, grey, or transparent colonies with a mild odor. H. influenzae will only grow on blood agar if other bacteria are present to release these factors from the red blood cells, forming 'satellite' colonies around these bacteria. For example, H. influenzae will grow in the hemolytic zone of Staphylococcus aureus on blood agar plates; the hemolysis of cells by S. aureus releases NAD which is needed for its growth. H. influenzae will not grow outside the hemolytic zone of S. aureus due to the lack of nutrients in these areas.
== Biography == Robert Brownlee was born October 21, 1942, in South Dakota. He founded Brownlee Labs in the 1970s, in the San Francisco Bay area, a manufacturer of columns and pumps for high-performance liquid chromatography systems. Bob Brownlee took the initiative "along with Tom Jupille, Steve Bakalyar, Nelson Cooke, Jerry Higgins and Ron Majors" to form the Bay Area Chromatography Colloquium. Bob Stevenson is quoted as saying in his Nine Lives of the California Separation Science Society that Brownlee Labs was "certainly one of the globe's leaders in HPLC column technology." In the 1980s, when Robert Brownlee was diagnosed with AIDS-related complex, he sold his company to Applied Biosystems of Foster City, California, in 1984. (Applied later merged with Perkin-Elmer). Sometime later, he began a new company, which was viewed by Applied as a competitor. A lawsuit was instituted and later settled (Brownlee v. Applied Biosystems, Inc., 1989-1 Trade Cas. (CCH) ¶ 68, (N.D. Cal. 1989) 8,14). In 1990, he was interviewed for an article in The Scientist about Applied Biosystems. "If you produce the first product for these virgins [scientists without such equipment], you have a big value added, and you can charge a big price for your product," Brownlee says. "That's the reason Applied Biosystems did so well." He also formed the Robert Brownlee Foundation, a private family foundation which supports, with grants, K–12 science.
Sources: en.wikipedia.org
where Ni is the number of molecules of molecular mass Mi. The mass average molecular mass can be determined by static light scattering, small angle neutron scattering, X-ray scattering, and sedimentation velocity. The ratio of the mass average to the number average is called the dispersity or the polydispersity index. The mass-average molecular mass, Mw, is also related to the fractional monomer conversion, p, in step-growth polymerization (for the simplest case of linear polymers formed from two monomers in equimolar quantities) as per Carothers' equation:
Impact Factor is not a perfect tool to measure the quality of articles but there is nothing better and it has the advantage of already being in existence and is, therefore, a good technique for scientific evaluation. Experience has shown that in each specialty the best journals are those in which it is most difficult to have an article accepted, and these are the journals that have a high impact factor. Most of these journals existed long before the impact factor was devised. The use of impact factor as a measure of quality is widespread because it fits well with the opinion we have in each field of the best journals in our specialty....In conclusion, prestigious journals publish papers of high level. Therefore, their impact factor is high, and not the contrary. As impact factors are a journal-level metric, rather than an article- or individual-level metric, this use is controversial. Eugene Garfield, the inventor of the JIF agreed with Hoeffel, but warned about the "misuse in evaluating individuals" because there is "a wide variation [of citations] from article to article within a single journal". Despite this warning, the use of the JIF has evolved, playing a key role in the process of assessing individual researchers, their job applications and their funding proposals. In 2007, The Journal of Cell Biology noted that:
A dosage of two to six 100 μg/day transdermal estradiol patches can achieve mean levels of estradiol in the area of 200 to 400 pg/mL and can be used as a form of high-dose estrogen therapy, for instance to suppress testosterone levels in the treatment of prostate cancer in men and in feminizing hormone therapy for transgender women. High-dose transdermal estradiol patches have also been studied in the treatment of postpartum depression and postpartum psychosis; in one such study, 200, 400, and 800 μg/day estradiol in the form of transdermal patches resulted in estradiol levels of 286 pg/mL, 675 pg/mL, and 1032 pg/mL, respectively. In another study, estradiol levels with 800 μg/day estradiol in the form of transdermal patches (Estraderm TTS) resulted in estradiol levels of 690 to 815 pg/mL. However, there is erratic absorption and considerable variation in estradiol levels using high-dose estradiol patches both between and within individuals, with one study finding that estradiol levels ranged from 70 pg/mL to 1,045 pg/mL (mean 460.7 pg/mL) with six 100 μg/day estradiol patches. The Prostate Adenocarcinoma: TransCutaneous Hormones (PATCH) study is a randomized controlled trial of high-dose transdermal estradiol patches versus gonadotropin-releasing hormone agonist monotherapy in the treatment of prostate cancer in approximately 2,200 men. It is specifically comparing three to four 100 μg/day estradiol patches (FemSeven) against goserelin implants. The study was started in March 2006 and is estimated for completion in August 2021.
Two pathways for PLP are currently known: one requires deoxyxylulose 5-phosphate (DXP), while the other does not, hence they are known as DXP-dependent and DXP-independent. These pathways have been studied extensively in Escherichia coli and Bacillus subtilis, respectively. Despite the disparity in the starting compounds and the different number of steps required, the two pathways possess many commonalities. The DXP-dependent pathway:
=== Protein purification === Polyhistidine-tags are often used for affinity purification of polyhistidine-tagged recombinant proteins expressed in Escherichia coli or other expression systems. Typically, cells are harvested via centrifugation and the resulting cell pellet lysed either by physical means or by means of detergents and enzymes such as lysozyme or any combination of these. At this stage, the lysate contains the recombinant protein among many endogenous proteins originating from the host cells. The lysate is exposed to affinity resin bound to a carrier matrix coupled with a divalent cation, either by direct addition of resin (batch binding) or by passing over a resin bed in a column format. The resin is then washed with buffer to remove proteins that do not specifically interact with bound cation and the protein of interest is eluted off the resin using buffer containing a high concentration of imidazole or a lowered pH. The purity and amount of protein can be assessed by methods such SDS-PAGE and Western blotting. Affinity purification using a polyhistidine-tag usually results in relatively pure protein. Protein purity can be improved by the addition of a low (20-40 mM) concentration of imidazole to the binding and/or wash buffers. However, depending on the requirements of the downstream application, further purification steps using methods such as ion exchange or size exclusion chromatography may be required. IMAC resins typically retain several prominent endogenous proteins as impurities. In E.
Sources: en.wikipedia.org
A problem with resonant cavities is that a high finesse cavity has very narrow cavity modes, often in the low kHz range (the width of the cavity modes is given by FSR/F, where FSR is the free-spectral range of the cavity, which is given by c/2L, where c is the speed of light and L is the cavity length). Since cw lasers often have free-running linewidths in the MHz range, and pulsed even larger, it is non-trivial to couple laser light effectively into a high finesse cavity. The most important resonant CEAS techniques are cavity ring-down spectrometry (CRDS), integrated cavity output spectroscopy (ICOS) or cavity enhanced absorption spectroscopy (CEAS), phase-shift cavity ring-down spectroscopy (PS-CRDS) and Continuous wave Cavity Enhanced Absorption Spectrometry (cw-CEAS), either with optical locking, referred to as (OF-CEAS), as has been demonstrated Romanini et al. or by electronic locking., as for example is done in the Noise-Immune Cavity-Enhanced Optical-Heterodyne Molecular Spectroscopy (NICE-OHMS) technique. or combination of frequency modulation and optical feedback locking CEAS, referred to as (FM-OF-CEAS). The most important non-resonant CEAS techniques are off-axis ICOS (OA-ICOS) or off-axis CEAS (OA-CEAS), wavelength modulation off-axis CEAS (WM-OA-CEAS), off-axis phase-shift cavity enhanced absorption spectroscopy (off-axis PS-CEAS). These resonant and non-resonant cavity enhanced absorption techniques have so far not been used that frequently with TDLAS. However, since the field is developing fast, they will presumably be more used with TDLAS in the future.
Piston syringes were used in ancient times. During the 1st century AD Aulus Cornelius Celsus mentioned the use of them to treat medical complications in his De Medicina. 9th century: The Iraqi/Egyptian surgeon Ammar ibn 'Ali al-Mawsili' described a syringe in the 9th century using a hollow glass tube, and suction to remove cataracts from patients' eyes, a practice that remained in use until at least the 13th century. Pre-Columbian Native Americans created early hypodermic needles and syringes using "hollow bird bones and small animal bladders". 1650: Blaise Pascal invented a syringe (not necessarily hypodermic) as an application of what is now called Pascal's law. 1844: Irish physician Francis Rynd invented the hollow needle and used it to make the first recorded subcutaneous injections, specifically a sedative to treat neuralgia. 1853: Charles Pravaz and Alexander Wood independently developed medical syringes with a needle fine enough to pierce the skin. Pravaz's syringe was made of silver and used a screw mechanism to dispense fluids. Wood's syringe was made of glass, enabling its contents to be seen and measured, and used a plunger to inject them. It is effectively the syringe that is used today. 1865: Charles Hunter coined the term "hypodermic", and developed an improvement to the syringe that locked the needle into place so that it would not be ejected from the end of the syringe when the plunger was depressed, and published research indicating that injections of pain relief could be given anywhere in the body, not just in the area of pain, and still be effective.
Nanotechnology. Actin-myosin systems act as molecular motors that permit the transport of vesicles and organelles throughout the cytoplasm. It is possible that actin could be applied to nanotechnology as its dynamic ability has been harnessed in a number of experiments including those carried out in acellular systems. The underlying idea is to use the microfilaments as tracks to guide molecular motors that can transport a given load. That is actin could be used to define a circuit along which a load can be transported in a more or less controlled and directed manner. In terms of general applications, it could be used for the directed transport of molecules for deposit in determined locations, which would permit the controlled assembly of nanostructures. These attributes could be applied to laboratory processes such as on lab-on-a-chip, in nanocomponent mechanics and in nanotransformers that convert mechanical energy into electrical energy.
The Litton detector was developed for sampling the light energy distribution in the rear focal-plane of a spherical lens for sampling geometric relationships and the spectral density distribution of objects recorded on film transparencies. The application of the Litton detector by Salzman et al. provided measurement at 32 small scattering angles between 0° and 30°, and averaging over a broad range of azimuthal angles as the most important angles are the forward angles for static light scattering. By 1980, Bartholi et al. had developed a new approach to measuring the scattering at discrete scattering angles by using an elliptical reflector to permit measurement at 30 polar angles over the range 2.5° ≤ θ ≤ 177.5° with a resolution of 2.1°. The commercialization of multiangle systems began in 1977 when Science Spectrum, Inc. patented a flow-through capillary system for a customized bioassay system developed for the USFDA. The first commercial MALS instrument incorporating 8 discrete detectors was delivered to S.C. Johnson and Son, by Wyatt Technology Company, in 1983, followed in 1984 with the sale of the first 15 detector flow instrument (Dawn-F) to AMOCO. By 1988, a three-dimensional configuration was introduced specifically to measure the scattering properties of single aerosol particles. At about the same time, the underwater device was built to measure the scattered light properties of single phytoplankton. Signals were collected by optical fibers and transmitted to individual photomultipliers.
Sources: en.wikipedia.org
Laboratory confirmation typically combines retention time matching on a chromatographic system with mass measurement. A reference standard of known identity is needed for a meaningful comparison. Sequence-level techniques can add further confirmation.
There is no single harmonised standard governing these products, and manufacturing conditions differ. Impurities may include truncated sequences, oxidation products, residual solvents, and counter-ions. Independent testing is often the only way to characterise a given lot.
Reported studies have looked at pigmentation, photoprotection, and metabolic or appetite-related endpoints in small experimental settings. Much of the evidence base is early-stage and limited in size. Questions about long-term effects and clinical relevance remain open.
The lyophilized powder is generally held at minus twenty degrees Celsius or below, away from light and moisture. Reconstituted solutions are typically refrigerated and used quickly. These practices derive from general peptide handling rather than a formal stability study.